GoodneyPPBeckAWNagleJ. National trends in lower extremity
bypass surgery, endovascular interventions, and major
amputations. J Vasc Surg.
2009;50:54–60.
2.
JonesDWSchanzerAZhaoY; Vascular Study Group of New
England. Growing impact of restenosis on the surgical
treatment of peripheral arterial disease. J Am Heart
Assoc.
2013;2:e000345.
3.
ConteMSBelkinMUpchurchGR. Impact of increasing comorbidity on
infrainguinal reconstruction: a 20-year perspective.
Ann Surg.
2001;233:445–452.
4.
KunlinJ.
[Long vein transplantation in treatment of ischemia caused by
arteritis.]. Rev Chir.
1951;70:206–235.
5.
BreslauRCDeweeseJA.
Successful endophlebectomy of autogenous venous bypass
graft. Ann Surg.
1965;162:251–254.
6.
MillsJLFujitaniRMTaylorSM.
The characteristics and anatomic distribution of lesions that
cause reversed vein graft failure: a fiveyear prospective
study. J Vasc Surg.
1993;17:195–206.
7.
DaviesMGHagenPO.
Pathophysiology of vein graft failure: a
review. Eur J Vasc Endovasc Surg.
1995;9:7–18.
8.
BandykDFSchmittDDSeabrookGR. Monitoring functional patency of in
situ saphenous vein bypasses: the impact of a surveillance protocol and
elective revision. J Vasc Surg.
1989;9:286–296.
9.
GasperWJOwensCDKimJM. Thirty-day vein remodeling is
predictive of midterm graft patency after lower extremity
bypass. J Vasc Surg.
2013;57:9–18.
10.
OwensCDWakeNJacotJG. Early biomechanical changes in lower
extremity vein grafts–distinct temporal phases of remodeling and wall
stiffness. J Vasc Surg.
2006;44:740–746.
11.
OwensCDWakeNConteMS. In vivo human lower extremity
saphenous vein bypass grafts manifest flow mediated
vasodilation. J Vasc Surg.
2009;50:1063–1070.
12.
OwensCDGasperWJRahmanAS. Vein graft failure.
J Vasc Surg. 2013 Oct 3. [Epub ahead of
print]
13.
JiangZTaoMOmalleyKAEstablished neointimal hyperplasia in vein grafts expands via
TGF-beta-mediated progressive fibrosis. Am J Physiol
Heart Circ Physiol. 2009;297:
H1200–1207.
14.
San
NorbertoEMTaylorJHCarreraS. Percutaneous transluminal angioplasty
with drug-eluting balloons for salvage of infrainguinal bypass
grafts. J Endovasc Ther.
2014;21:12–21.
15.
ConteMSBandykDFClowesAW; PREVENT III Investigators.
Results of PREVENT III: a multicenter, randomized trial of
edifoligide for the prevention of vein graft failure in lower extremity
bypass surgery. J Vasc Surg.
2006;43:742–751.
16.
BerceliSAHeveloneNDLipsitzSR. Surgical and endovascular revision of
infrainguinal vein bypass grafts: analysis of midterm outcomes from the
PREVENT III trial. J Vasc Surg.
2007;46:1173–1179.
17.
WerkMLangnerSReinkensmeierB. Inhibition of restenosis in
femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral
paclitaxel randomized pilot trial.
Circulation.
2008;118:1358–1365.
18.
StabileEVirgaVSalemmeL. Drugeluting balloon for treatment of
superficial femoral artery in-stent restenosis. J Am
Coll Cardiol.
2012;60:1739–1742.
19.
IndermuehleABahlRLanskyAJ. Drugeluting balloon angioplasty for
in-stent restenosis: a systematic review and meta-analysis of randomised
controlled trials. Heart.
2013;99:327–333.
20.
LiuXZhuSWangT. Paclitaxel modulates TGFbeta
signaling in scleroderma skin grafts in immunodeficient
mice. PLoS Med.
2005;2:e354.
21.
WangCSongXLiY. Low-dose paclitaxel ameliorates
pulmonary fibrosis by suppressing TGF-β1/SMAD3 pathway via miR-140
upregulation. PLoS One.
2013;8:e70725.
22.
HerdegCOberhoffMBaumbachA. Local paclitaxel delivery for the
prevention of restenosis: biological effects and efficacy in
vivo. J Am Coll Cardiol.
2000;35:1969–1976.
23.
WerkMAlbrechtTMeyerDR. Paclitaxel-coated balloons reduce
restenosis after femoro-popliteal angioplasty: evidence from the randomized
PACIFIER trial. Circ Cardiovasc Interv.
2012;5:831–840.
24.
SandboNNgamCTorrE. Control of myofibroblast
differentiation by microtubule dynamics through a regulated localization of
mDia2. J Biol Chem.
2013;288:15466–15473.
